Ponatinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ponatinib: From Unspecified Original Indication to Gingival Fibromatosis
One-Sentence Summary
Ponatinib (DrugBank ID DB08901) has no original indication or mechanism-of-action data on file in this evidence pack. The TxGNN model’s top-ranked prediction proposes potential effectiveness for Gingival Fibromatosis, but this specific prediction is currently supported by 0 clinical trials and 0 publications — it is a pure AI embedding-similarity output with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no original indications or market licenses on file (data gap) |
| Predicted New Indication | Gingival Fibromatosis |
| TxGNN Prediction Score | 99.04% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Ponatinib is not available in this evidence pack (flagged as a High-severity data gap). However, literature attached to other candidate indications in this same pack (not to gingival fibromatosis specifically) consistently describes Ponatinib as a third-generation, multi-target tyrosine kinase inhibitor acting on BCR-ABL, FGFR, PDGFR, SRC, KIT, and RET, historically used in hematologic malignancies (e.g., PMID 37399979, PMID 36927623).
For the top-ranked prediction itself — Gingival Fibromatosis — the evidence pack’s own rationale is explicit: there is no known kinase-driven mechanism connecting Ponatinib’s target profile to this disease. The prediction is described as “purely a TxGNN embedding similarity output, with no literature or trial support” (repurposing_rationale.mechanistic_link). In other words, the model surfaced a statistical association in the knowledge graph, not a biologically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No marketing authorizations on file — the drug is recorded as not currently marketed in this jurisdiction (0 licenses).
Cytotoxicity
(Ponatinib is included here as an antineoplastic based on class-level context found elsewhere in the evidence pack — literature describes it as a tyrosine kinase inhibitor used in leukemia treatment — though drug-level DrugBank categories and toxicity data are not available in this pack.)
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (multi-target tyrosine kinase inhibitor: BCR-ABL/FGFR/PDGFR/SRC/KIT/RET) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Based on toxicity signals reported in pack literature for this drug class: cardiovascular monitoring (blood pressure, ECG), pulmonary symptoms, renal function, CBC — final list per SmPC |
| Handling Protection | Oral hazardous/antineoplastic drug handling precautions recommended pending SmPC confirmation |
Safety Considerations
Please refer to the SmPC for safety information. (All key warnings, contraindications, and DDI fields in this evidence pack are unfilled; the missing TFDA/regulatory label data is flagged as a Blocking gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Gingival Fibromatosis) has no supporting clinical trials or literature, and the evidence pack itself states there is no known mechanistic link — this is a pure model-score artifact. Combined with a Blocking gap on safety labeling data, this candidate cannot proceed past initial screening.
To proceed, the following is needed:
- TFDA/regulatory safety labeling (warnings, contraindications) — Blocking gap
- Detailed mechanism-of-action data from DrugBank — High-priority gap
- Any preclinical or mechanistic rationale specifically linking Ponatinib to gingival fibromatosis, if it exists
- Re-evaluate other candidates within this same pack that carry stronger evidence (see below)
Note: Other Predictions in This Evidence Pack
This pack contains 10 ranked predictions for Ponatinib. The top-scored one (above) has no evidence, but two lower-ranked, lower-score predictions show materially stronger support and may warrant separate evaluation:
| Rank | Disease | Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 2 | Liposarcoma | 99.00% | L4 | Research Question |
| 9 | Lung benign neoplasm | 98.83% | L3 | Research Question |
Both are supported by literature suggesting FGFR/PDGFR/SRC pathway relevance (e.g., kinase screening in liposarcoma cell lines; FGFR1 mRNA/copy-number-based patient preselection for Ponatinib in lung tumors), unlike the zero-evidence gingival fibromatosis prediction. If a “Go” pathway is sought within this candidate set, ranks 2 and 9 are the more defensible starting points.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.